PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Research Article

Volume 4 Issue 4

Tuberculosis: History, Pathophsiology, Antituberculosis Drugs and Herbal Approach of The Treatment

Shivang Yadav* and Abhishek Kumar

March 20, 2024

DOI : 10.56831/PSMPH-04-134


Tuberculosis (TB) is a major health issue in underdeveloped nations, with India having the largest TB burden. The disease is caused by the bacteria Mycobacterium tuberculosis and has been a leading cause of death in India. The search for anti-TB agents has received extensive study, and the immune mechanisms and hereditary risk factors for TB-related lung injury are being explored. The history of TB treatment has seen remarkable advancements since the invention of streptomycin in 1947. In 2015, the World Health Organization recorded 9.6 million new cases of tuberculosis (TB) and 1.5 million fatalities related to the disease. Amongst these cases, 5% were expected to be multidrug-resistant TB. The disease has a long history, with evidence of spinal caries and TB in ancient times. The document provides information on the diagnosis and treatment of tuberculosis. It discusses various diagnostic methods such as microscopy, antigen detection, and tuberculin skin testing. Additionally, it outlines the treatment intentions for tuberculosis and the WHO’s standardized DOTS/cease TB program. The document also details the metabolism, route of elimination, and toxicity of anti-tuberculosis drugs like Ethambutol and Ethionamide. Various methods for the extraction and quantitative analysis of artemisinin, a compound with potential medicinal properties has been discussed. These methods include liquid chromatography-mass spectrometry, ultrasonic-assisted maceration, Soxhlet extraction, microwave-assisted extraction, and supercritical fluid extraction. The challenges of quantifying artemisinin due to its low concentration and thermolability are also highlighted.

Keywords: Tuberculosis; Mycobacterium; WHO; Artemisinin; Taxus; Vetiveria; Propolis


  1. Tripathi KD. Essentials of medical pharmacology. 8th ed.
  2. Tejas M Dhameliya., et al. “Recent Advancements and Developments in Search of Anti- tuberculosis Agents: A Quinquennial Update and Future Directions”. Journal of MolecUlar Structure (2021).
  3. Herzog H. “History of tuberculosis”. Respiration 65.1 (1998): 5-15.
  4. Eshetie S., et al. “Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis”. BMC Infect Dis 17.1 (2017): 219.
  5. Daniel Thomas, Bates Joseph and Downes Katharine. History of Tuberculosis (2014).
  6. Tiemersma EW., et al. “Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients A Systematic Review”. PLoS ONE 6.4 (2011): e17601.
  7. Restrepo BI and Schlesinger LS. “Impact of diabetes on the natural history of tuberculosis”. Diabetes Res Clin Pract 106.2 (2014): 191-9.
  8. Viswanathan V., et al. “Effect of diabetes on treatment outcome of smear positive Pulmonary tuberculosis - A report from South India”. Journal of Diabetes and Its Complications (2014).
  9. David P. Maison. “Tuberculosis pathophysiology and anti-VEGF intervention”. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 27 (2022): 100300.
  10. Janin YL. “Antituberculosis drugs: ten years of research”. Bioorg Med Chem 15.7 (2007): 2479-513.
  11. Knechel NA. “Tuberculosis: pathophysiology, clinical features, and diagnosis”. Crit Care Nurse 29.2 (2009): 34-43; quiz 44.
  12. Rodriguez-Takeuchi SY, Renjifo ME and Medina FJ. “Extrapulmonary Tuberculosis: Pathophysiology and Imaging Findings”. Radiographics 39.7 (2019): 2023-2037.
  13. Ravimohan S., et al. “Tuberculosis and lung damage: from Epidemiology to pathophysiology”. Eur Respir Rev 27 (2018): 170077.
  16. Koch A and Mizrahi V. “Mycobacterium tuberculosis”. Trends Microbiol 26.6 (2018): 555-556.
  17. Wejse C., et al. “TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course”. Scand J Infect Dis 40.2 (2008): 111-20.
  18. Shingadia D and Novelli V. “Diagnosis and treatment of tuberculosis in children”. Lancet Infect Dis 3.10 (2003): 624-32. Erratum in: Lancet Infect Dis 4.4 (2004): 251.
  19. Huang Y., et al. “Review and Updates on the Diagnosis of Tuberculosis”. J. Clin. Med 11 (2022): 5826.
  20. Bereda G. “First Line Anti-Tuberculosis Medication: Current and Ongoing Clinical Management”. Journal of Molecular Biology and Drug Design 1.1 (2022): 1-10.
  21. Simon Tiberi., et al. “Classifying new anti-tuberculosis drugs: rationale and future perspectives”. International Journal of Infectious Diseases 56 (2017): 181-184.
  22. Arbex MA., et al. “Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs”. J Bras Pneumol 36.5 (2010): 626-40.
  23. Nick Lee and Hoang Nguyen. Ethambutol. Statpearls.
  24. Chan RY and Kwok AK. “Ocular toxicity of ethambutol”. Hong Kong Med J 12.1 (2006): 56-60.
  25. Ethambutol. DRUGBANK online
  26. Sundell J., et al. “Population Pharmacokinetics and pharmacogenetics of Ethambutol in adult patients coinfected with Tuberculosis and HIV”. Antimicrob Agents Chemother 64 (2020): e01583-19.
  27. Vale N, Gomes P and Santos HA. “Metabolism of the antituberculosis drug ethionamide”. Curr Drug Metab 14.1 (2013): 151-8.
  28. Baulard AR., et al. “Activation of the pro-drug ethionamide is regulated in mycobacteria”. J Biol Chem 275.36 (2000): 28326-31.
  30. drug.htm#:~:text=Trecator%20is%20primarily%20indicated%20for,the%20rapid%20dev elopment%20of%20resistance.
  31. Ntutela S., et al. “Efficacy of Artemisia afra phytotherapy in experimental tuberculosis”. Tuberculosis (Edinb) 89.Suppl 1 (2009): S33-40.
  32. Devendra Kumar Mishra and Shubham Shukla. “A review on herbal treatment of tuberculosis”. International Research Journal of Pharmacy and Medical Sciences (IRJPMS) 3.5 (2020): 6-10.
  33. Davies-Bolorunduro., et al. “Bioprospecting for antituberculosis natural products - A review”. Open Chemistry 19.1 (2021): 1074-1088.
  34. Kundan Singh Bora and Anupam Sharma. “The Genus Artemisia: A Comprehensive Review”. Pharmaceutical Biology 49.11 (2011): 101-109.
  35. Kiani BH., et al. “Artemisia afra and Artemisia annua Extracts have Bactericidal Activity against Mycobacterium tuberculosis in Physiologically Relevant carbon Sources and Hypoxia”. Pathogens 12 (2023): 227.
  36. Bilia AR., et al. “Essential Oil of Artemisia annua L.: An Extraordinary Component with Numerous Antimicrobial Properties”. Evid Based Complement Alternat Med (2014): 159819.
  37. Woerdenbag HJ., et al. “Artemisinin, Related Sesquiterpenes, and Essential Oil in Artemisia annua During a Vegetation Period in Vietnam”. Planta Med 60.3 (1994): 272-5.
  38. Choi WH. “Novel Pharmacological Activity of Artesunate and Artemisinin: Their Potential as Anti-Tubercular Agents”. J Clin Med 6.3 (2017): 30.
  39. Miller MJ., et al. “Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria”. J Am Chem Soc 133.7 (2011): 2076-9.
  40. Patel YS, Mistry N and Mehra S. “Repurposing artemisinin as an anti-mycobacterial agent in synergy with rifampicin”. Tuberculosis (Edinb) 115 (2019): 146-153.
  41. N Erdemoglu, B Sener and P Palittapongarnpim. “Antimycobacterial Activity of Taxusbaccata”. Pharmaceutical Biology 41.8 (2003): 614-615.
  42. Dumitraş DA., et al. “Phytochemical Characterization of Taxus baccata L. Aril with Emphasis on Evaluation of the Antiproliferative and Pro-Apoptotic Activity of Rhodoxanthin”. Antioxidants (Basel) 11.6 (2022): 1039.
  43. Ali MT., et al. “Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach”. Sci Rep 8.1 (2018): 12238.
  44. Tanvir Kaur., et al. “Treatment of Tuberculosis by Natural Drugs: A Review”. Plant Archives 19.2 (2019): 2168-2176.